Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

04 Mar 2024
www.globenewswire.com
Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)
Oslo, Norway, 4 March 2024
Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international pharmaceutical companies. CF Pharma has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs). The group/company currently has five commercial APIs on the market, with another eight APIs under development.
The transaction price consists of a base price and an earn-out- element, with an agreed cap of MEUR 1.6.
“We have had positive discussions with CF Pharma management and the majority shareholders for some time, to evaluate different partnership models. I am very pleased to announce that Vistin Pharma now has acquired a minority stake in CF PharmaCF Pharma. We see this as a first agreed step in a potential closer partnership in the future, which can broaden our product portfolio and form an important basis for future growth. The cooperation with CF Pharma is a first move in order for Vistin Pharma to execute on the strategy to become a multi-product European API Contract Development and Manufacturing Organization (API CDMO)”, says Magnus Tolleshaug, CEO in Vistin Pharma."
For further information, please contact:
Magnus Tolleshaug
CEO
+47 48 40 52 46
magnus.tolleshaug@vistin.com
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.